Sponsors / AKBA
AKBA

Akebia Therapeutics

Company identity has not yet been verified

See the trials and registry edits we have linked to this sponsor, the company or organization running a study. Choose “Follow company” to add it to your watchlist and find its recorded changes in your dashboard.

Follow company
5Trials in this database
14Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)NCT04313153Akebia TherapeuticsPhase 3Completed2021-11-26Actual
Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis SubjectsNCT04707768Akebia TherapeuticsPhase 3Completed2023-01-06Actual
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3GNCT06419205Akebia TherapeuticsPhase 2Recruiting2028-02Estimated
To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center HemodialysisNCT06901505Akebia TherapeuticsPhase 3Completed2026-08-12Actual
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)NCT07268638Akebia TherapeuticsPhase 2Recruiting2027-06Estimated

Latest recorded trial changes

A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G

NCT06419205 · Akebia Therapeutics

Primary outcomes · main study measuresText edit · unverified significance
− Previous value

measure: Incidence of adverse events (AEs) to evaluate the safety of ADX-097

+ Updated value

measure: Number of participants reporting treatment emergent adverse events (TEAEs)

Check registry source · The saved outcome text may be shortened. Check the source for full wording.